Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharmacol Exp Ther ; 363(1): 104-113, 2017 10.
Article in English | MEDLINE | ID: mdl-28778859

ABSTRACT

The increasing availability of prescription opioid analgesics for the treatment of pain has been paralleled by an epidemic of opioid misuse, diversion, and overdose. The development of abuse-deterrent formulations (ADFs) of conventional opioids such as oxycodone and morphine represents an advance in the field and has had a positive but insufficient impact, as most opioids are still prescribed in highly abusable, non-ADF forms, and abusers can tamper with ADF medications to liberate the abusable opioid within. The abuse liability of mu-opioid agonists appears to be dependent on their rapid rate of entry into the central nervous system (CNS), whereas analgesic activity appears to be a function of CNS exposure alone, suggesting that a new opioid agonist with an inherently low rate of influx across the blood-brain barrier could mediate analgesia with low abuse liability, regardless of formulation or route of administration. NKTR-181 is a novel, long-acting, selective mu-opioid agonist with structural properties that reduce its rate of entry across the blood-brain barrier compared with traditional mu-opioid agonists. NKTR-181 demonstrated maximum analgesic activity comparable to that of oxycodone in hot-plate latency and acetic-acid writhing models. NKTR-181 was distinguishable from oxycodone by its reduced abuse potential in self-administration and progressive-ratio break point models, with behavioral effects similar to those of saline, as well as reduced CNS side effects as measured by the modified Irwin test. The in vitro and in vivo studies presented here demonstrate that NKTR-181 is the first selective mu-opioid agonist to combine analgesic efficacy and reduced abuse liability through the alteration of brain-entry kinetics.


Subject(s)
Analgesics, Opioid/pharmacology , Morphinans/pharmacology , Substance-Related Disorders/prevention & control , Analgesics, Opioid/chemistry , Analgesics, Opioid/metabolism , Animals , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/metabolism , Caco-2 Cells , Dose-Response Relationship, Drug , Drug Compounding , Humans , Male , Morphinans/chemistry , Morphinans/metabolism , Permeability , Rats , Rats, Sprague-Dawley , Receptors, Opioid, mu/metabolism , Time Factors
2.
J Pharm Sci ; 98(8): 2847-56, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19408293

ABSTRACT

Polyethylene glycol (PEG) polymers are large amphiphilic molecules that are highly hydrated in solution. To explore the permeability properties of different sized PEG polymers across epithelial membranes in vivo, we examined the absorption of fluorescently labeled PEG conjugates sized 0.55-20 kDa from the lung, since this system provides a reservoir that limits rapid diffusion of molecules away from the site of delivery and enables permeability over longer times to be examined. Following intratracheal delivery in rats, the PEG polymers underwent absorption with first-order kinetics described by single exponential decay curves. PEG size produced a marked influence on the rate of uptake from the lung, with half-lives ranging from 2.4 to 13 h, although above a size of 5 kDa, no further change in rate was observed. PEG size likewise affected retention in alveolar macrophages and in lung tissue; whereas smaller PEG sizes (<2 kDa) were effectively cleared within 48 h, larger PEG sizes (>5 kDa) remained in lung cells and tissue for up to 7 days. These data demonstrate that PEG polymers can be absorbed across epithelial membranes and that PEG size plays a dominant role in controlling the rate and mechanism of absorption.


Subject(s)
Polyethylene Glycols/chemistry , Polyethylene Glycols/metabolism , Absorption/drug effects , Absorption/physiology , Animals , Dose-Response Relationship, Drug , Male , Particle Size , Permeability/drug effects , Polyethylene Glycols/pharmacology , Polymers/chemistry , Polymers/metabolism , Rats , Rats, Sprague-Dawley , Respiratory Mucosa/drug effects , Respiratory Mucosa/metabolism
3.
Am J Physiol Heart Circ Physiol ; 287(6): H2659-65, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15308476

ABSTRACT

Cardiac ischemia-reperfusion (I/R) injury is accompanied by intracellular acidification that can lead to cytosolic and mitochondrial calcium overload. However, the effect of cytosolic acidification on mitochondrial pH (pHm) and mitochondrial Ca2+ (Cam2+) handling is not well understood. In the present study, we tested the hypothesis that changes in pHm during cytosolic acidification can modulate Cam2+ handling in cardiac mitochondria. pHm was measured in permeabilized rat ventricular myocytes with the use of confocal microscopy and the pH-sensitive fluorescent probe carboxyseminaphthorhodafluor-1. The contributions of the mitochondrial Na+/H+ exchanger (NHEm) and the K+/H+ exchanger (KHEm) to pHm regulation were evaluated using acidification and recovery protocols to mimic the changes in pH observed during I/R. Cam2+ transport in isolated mitochondria was measured using spectrophotometry and fluorimetry, and the mitochondrial membrane potential was measured using a tetraphenylphosphonium electrode. Cytosolic acidification (pH 6.8) resulted in acidification of mitochondria. The degree of mitochondrial acidification and recovery was found to be largely dependent on the activity of the KHEm. However, the NHEm was observed to contribute to the recovery of pHm following acidification in K+-free solutions as well as the maintenance of pHm during respiratory inhibition. Acidification resulted in mitochondrial depolarization and a decrease in the rate of net Cam2+ uptake, whereas restoration of pH following acidification increased Cam2+ uptake. These findings are consistent with an important role for cytosolic acidification in determining pHm and Cam2+ handling in cardiac mitochondria under conditions of Ca2+ overload. Consequently, interventions that alter pHm can limit Cam2+ overload and injury during I/R.


Subject(s)
Acids/metabolism , Amiloride/analogs & derivatives , Calcium/metabolism , Mitochondria/metabolism , Myocytes, Cardiac/metabolism , Amiloride/pharmacology , Animals , Anti-Arrhythmia Agents/pharmacology , Choline/pharmacology , Cytosol/metabolism , Hydrogen-Ion Concentration , Male , Membrane Potentials/drug effects , Membrane Potentials/physiology , Potassium Chloride/pharmacology , Rats , Rats, Sprague-Dawley , Sodium-Hydrogen Exchangers/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...